Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Essential tremor patients managed through in-person and telemedicine have similar experiences with prescribed non-invasive neuromodulation therapy
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
011
This real-world evidence study assessed the effect of prescription setting on patient experience with an at-home non-invasive neuromodulation therapy.
Telemedicine can increase accessibility to healthcare, but it is unclear how remote versus in-person patient engagement, especially during an initial visit requiring patient evaluation, affects therapeutic outcomes.
This analysis evaluated de-identified data from essential tremor patients prescribed a wrist-worn Transcutaneous Afferent Patterned Stimulation (TAPS) device (Cala Health, Burlingame, CA, USA). The device tracked therapy usage and, for a subset of sessions, measured tremor motion using an onboard accelerometer before and after a therapeutic session. Patient experience was evaluated by (i) time from prescription to shipment to the patient, (ii) at-home therapy usage, and (iii) therapy efficacy, quantified using median improvement in device-measured tremor power.
The time elapsed from prescription to when patients received the device was comparable between the cohorts (26±37 days all, 26±41 days telemedicine cohort; p=0.63). 265 patients, 13 of which were from a single telemedicine prescriber, had the device for at least 30 days and had at least 10 sessions of valid accelerometer data available for analysis. Both patient cohorts had similar device use patterns, with patients typically completing 1-2 sessions/day on 2.6 days/week (median; range 0-7 days/week). Objective motion data from 12,731 sessions (613 from telemedicine patients) showed 88% of all patients (77% telemedicine patients; across-group p=0.24) had ≥2-fold improvement in tremor power during their most severe sessions when tremor relief might be most needed, and 53% of all patients (31% telemedicine patients; across-group p=0.12) had ≥2-fold improvement in tremor power aggregated over all sessions.
No differences were observed in patient experience with Cala Trio, suggesting that patient management via telemedicine is a feasible way to evaluate and treat patients without sacrificing health outcomes.
Authors/Disclosures
Salima Brillman, MD
PRESENTER 		The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cala Health. The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda. The institution of Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for USWorldMeds. Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acadia. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Adamas. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for USWorld Meds. Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file